Argos Therapeutics, Inc. Presents Positive Phase 2 Data for Arceli(TM) Dendritic Cell-based Immunotherapy in Advanced RCC at American Society of Clinical Oncology

DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 in a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL. AGS-003 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is individualized to each patient’s unique tumor.